Tristel (R1V) AI Stock Analysis

1 Followers

Tristel

(Frankfurt:R1V)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Proprietary technology and defensible market positionA proprietary technology position supported by patents, applications and difficult-to-replicate know-how can protect product differentiation over several years. This strengthens Tristel’s ability to win regulated healthcare accounts, support premium margins and build adoption as clinical evidence and guidelines expand.

Negative Factors

Legacy product declines and regional competitionDeclining legacy products and competitive or tender-related pressure can offset growth from newer offerings, particularly in mature markets. If these headwinds persist, they could make consolidated growth less predictable and require greater commercial investment to defend existing positions.

Tristel (R1V) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 189.89M
Dividend Yield: 3.42%
Average Volume (3M): 424
Price to Earnings (P/E): 23.7
Beta (1Y): 0.26
Revenue Growth: 6.41%
EPS Growth: 15.95%
Country: Germany
Employees: 282
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Tristel Business Overview & Revenue Model

Company Description

Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core d...

Tristel Earnings Call Summary

Earnings Call Date:Oct 18, 2026(Q4-2026)|% Change Since:-6.53%|Next Earnings Date:Feb 21, 2027

Earnings Call SentimentPositive

The call was strongly optimistic. The company reported record revenue, double-digit growth, higher adjusted profit before tax, a 31% adjusted EBITDA margin, strong cash generation, no debt and a growing dividend. Management also highlighted substantial U.S. pipelines, new product launches, digital platform adoption, clinical evidence and significant market opportunities. The main negatives were legacy product declines, isolated competitive and tender-related challenges, higher tax expense, a one-off impairment and employee-share-scheme dilution. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Record Revenue and Double-Digit Growth

Revenue reached a record GBP 51.1 million, representing 10% growth year-over-year. Growth was 5% in the U.K. and 13% overseas, while Americas sales tripled.

Negative Updates

Legacy Product Decline

Legacy products declined year-over-year at the group level. In New Zealand, the decline in legacy products offset slight growth in medical device decontamination and dragged down overall performance.

Company Guidance

Management said results remain in line with expectations and the business is firmly on track to meet its financial targets, with a commitment out to 2030 of revenue growth that's not less than double digit on an annual basis, an EBITDA margin that exceeds 25% and a progressive year-on-year dividend growth policy. Priorities include accelerating U.S. growth, increasing commercial, clinical and R&D investment, expanding existing and new markets, launching Unifoam in January in a first phase market, and targeting an opportunity somewhere in the magnitude of GBP 40 million from bringing direct markets up to the median distribution, with further opportunity up to GBP 60 million from internal benchmarks.

Tristel Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:R1V against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:SN	72Outperform	GBP 9.35B	21.11	12.25%	2.47%	2.17%	27.33%
GB:CTEC	71Outperform	GBP 4.66B	54.03	8.40%	2.20%	1.94%	-43.71%
GB:AMS	67Neutral	GBP 611.34M	166.47	1.44%	1.66%	6.05%	-60.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:SUN	49Neutral	GBP 3.03M	-3.25	-15.47%	―	-3.68%	20.00%
GB:CVSG	48Neutral	GBP 911.73M	55.52	5.91%	0.65%	5.88%	-9.18%

* Healthcare Sector Average

Performance Comparison

DE:R1V and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:R1V	Tristel plc	4.72	0.76	19.22%
GB:AMS	Advanced Medical Solutions	283.00	71.96	34.09%
GB:CTEC	ConvaTec Group plc	254.00	23.70	10.29%
GB:CVSG	CVS Group plc	1388.00	180.00	14.90%
GB:SUN	Surgical Innovations Group Plc	0.33	-0.25	-43.97%
GB:SN	Smith & Nephew (UK)	1190.00	-43.28	-3.51%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Tristel AI Stock Analysis